624 related articles for article (PubMed ID: 27678281)
1. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
2. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.
Kaur M; Singh PK; Singh M; Bahadur R; Silakari O
Mol Divers; 2018 Feb; 22(1):95-112. PubMed ID: 29138965
[TBL] [Abstract][Full Text] [Related]
4. Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.
Kaur M; Singh M; Silakari O
Future Med Chem; 2017 Jul; 9(11):1193-1211. PubMed ID: 28722479
[TBL] [Abstract][Full Text] [Related]
5. Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening.
Jasuja H; Chadha N; Singh PK; Kaur M; Bahia MS; Silakari O
Comput Biol Chem; 2018 Oct; 76():109-117. PubMed ID: 29990790
[TBL] [Abstract][Full Text] [Related]
6. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol.
Kaur M; Kumari A; Bahia MS; Silakari O
J Mol Graph Model; 2013 Feb; 39():165-75. PubMed ID: 23280414
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.
Kumar V; Parate S; Danishuddin ; Zeb A; Singh P; Lee G; Jung TS; Lee KW; Ha MW
Front Cell Infect Microbiol; 2022; 12():909111. PubMed ID: 35846777
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.
Jasuja H; Chadha N; Kaur M; Silakari O
Mol Divers; 2014 May; 18(2):253-67. PubMed ID: 24415188
[TBL] [Abstract][Full Text] [Related]
10. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives.
Faris A; Hadni H; Ibrahim IM; Elhallaoui M
J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
12. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2.
Jasuja H; Chadha N; Kaur M; Silakari O
SAR QSAR Environ Res; 2014; 25(8):617-36. PubMed ID: 25148044
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
Wang JL; Cheng LP; Wang TC; Deng W; Wu FH
J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
18. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
19. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
